Invention Grant
- Patent Title: Anti-CD40 antibodies and uses thereof
-
Application No.: US17048954Application Date: 2019-04-19
-
Publication No.: US11976123B2Publication Date: 2024-05-07
- Inventor: Jieyi Wang , Yi Wu
- Applicant: Lyvgen Biopharma Holdings Limited
- Applicant Address: KY Grand Cayman
- Assignee: LYVGEN BIOPHARMA HOLDINGS LIMITED
- Current Assignee: LYVGEN BIOPHARMA HOLDINGS LIMITED
- Current Assignee Address: KY
- Agency: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
- Priority: WO TCN2018083864 2018.04.20
- International Application: PCT/US2019/028364 2019.04.19
- International Announcement: WO2019/204756A 2019.10.24
- Date entered country: 2020-10-19
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C07H21/04 ; C07K16/28 ; C07K16/42 ; C07K16/46 ; C12N5/02 ; C12N15/00
Abstract:
Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders.
Public/Granted literature
- US20210179727A1 ANTI-CD40 ANTIBODIES AND USES THEREOF Public/Granted day:2021-06-17
Information query
